Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib

Edward Kim, Mark M. Zalupski

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Progression on first-line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib-resistant GIST include agents that target KIT/PDGFR with greater potency or possess broader kinase inhibition profiles including VEGFR. To circumvent secondary mutations in KIT/PDGFR, inhibition of the downstream signaling in PI3K/Akt/mTOR pathway and enhanced degradation of KIT/PDGFR are also under investigation. J. Surg. Oncol. 2011; 104:901-906.

Original languageEnglish (US)
Pages (from-to)901-906
Number of pages6
JournalJournal of Surgical Oncology
Issue number8
StatePublished - Dec 2011
Externally publishedYes


  • GIST
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib'. Together they form a unique fingerprint.

Cite this